Farallon Capital Management
Farallon Capital Management, founded by Thomas Steyer in 1986, is a global institutional investment firm based in San Francisco. The firm is currently managed by Andrew Spokes, who has upheld its reputation for employing a research-intensive, risk-aware investment approach. Farallon’s investment philosophy emphasizes value-oriented, event-driven strategies across asset classes.
AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings — not the fund's actual assets under management.
- Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
- For PUT and CALL options, the reported Value is the notional value of the underlying shares — not the option premium paid. This significantly overstates the actual capital at risk.
- Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
- 13F filings cover institutional managers with ≥$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.
Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.
Portfolio Holdings
Top 2 positions
| Ticker | Issuer | Notional | Port % | Allocation |
|---|---|---|---|---|
| EXAS | $650.5M | 73.61% | 73.6% | |
| RNAM | $233.2M | 26.39% | 26.4% |
Quarter-on-Quarter Activity
New Positions
None this quarter
Exited Positions
None this quarter
Increased
None this quarter
Trimmed
None this quarter
Quarter Activity
During the quarter, Farallon Capital Management made no changes to its portfolio. There were no new positions, exits, or adjustments in the size of existing investments. This indicates a period of static investment strategy for the fund.
AI Commentary
<p>Farallon Capital Management's portfolio is highly concentrated in the healthcare sector, specifically in biotechnology. As of the latest reporting period, the fund holds only two positions, with Exact Sciences Corp (EXAS) making up 73.6% of the portfolio, valued at $650 million, and Avidity Biosciences Inc (RNAM) comprising the remaining 26.4%, valued at $233 million. This focused investment strategy highlights a strong conviction in these biotech entities, suggesting a deep bullish outlook on their potential for growth and innovation within the healthcare industry.</p> <p>The fund's activity in the most recent quarter shows no new positions were opened, and none were closed, increased, or decreased. This lack of movement could signal a steady confidence in their current holdings, particularly in the biotechnology sector. By maintaining their positions unchanged, Farallon Capital Management may be indicating a continued positive outlook on the biotech sector's fundamentals or possibly awaiting more definitive market signals before making further portfolio adjustments.</p>